Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.

Abstract: Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA/RNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes.

Abstract: Encryption of an image is achieved through application of a homomorphic encryption function to produce cipher images for each image. Encryption is performed individually on sub-values of a pixel's intensity value, wherein the pixel's intensity value can be described as a sum of the smaller numerical sub-values. The encrypted values for each sub-value form encrypted images that can be transferred or stored on insecure media. Separate encryption approaches can be applied to individual sets of the numerical sub-values to improve security.

Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.

Abstract: C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof.

Abstract: The present disclosure provides methods of applying a filtering coating to a substrate, comprising: depositing a solution on a surface of a substrate, wherein the solution comprises an organic solvent with nanorods dispersed within the solvent. Evaporation of the solution is allowed and/or controlled to increase a volume fraction of the nanorods in the solution as a function of the evaporation. Thus, an aligned deposit of the nanorods is provided as a function of the evaporation, wherein the aligned deposit of nanorods includes at least thousands of the nanorods with at least a majority of the nanorods aligned relative to a length of the nanorods.

Abstract: An organogel including a base fluid, cetyl alcohol, and a gelling agent provided in an amount to cause the fluid to change from a liquid state to a gelled state at temperatures below at least 25° C. A nanofluid including an organogel and a nanoparticle component which permits the nanofluid to change from a liquid state to a gelled state at temperatures below at least 25° C., the gelled state helping to maintain the nanoparticle component suspended throughout the base fluid; and a method for preparing a gelled nanofluid.

Abstract: Systems, methods and apparatus for secure encryption and decryption of a file may be provided which may include generating, by a first processor, a plurality of encryption isokeys, wherein the plurality of encryption isokeys include a first public isokey, a second public isokey, and a private isounit; and encrypting, by the first processor, ciphertext associated with a message based on the plurality of encryption isokeys. The approach may also include receiving, by a second processor, the ciphertext associated with the message; generating, by the second processor, a plurality of decryption isokeys, wherein the plurality of decryption isokeys include the private isounit, a private decryption isokey, and the first public isokey; and decrypting, by the second processor, the message associated with the ciphertext based on the plurality of decryption isokeys.

Abstract: Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes.

Abstract: An aerial device is provided. The aerial device includes a processor and a memory that includes instructions configured to cause the processor to perform certain operations when the processor executes the instructions. The operations may include receiving a first signal indicative of a first position of the aerial device. The operations may also include generating, based on the first signal and based on a randomly or pseudo-randomly generated sequence, a second signal configured to actuate flight hardware of the aerial device to a second position.

Abstract: The present disclosure provides small complementary RNAs (scRNAs), compositions containing the same, and methods for using such small complementary RNAs as antivirals. The present disclosure provides, in more specific embodiments, scRNAs that are single-stranded and which are about 20-30 nucleotides (nt) long, and which are complementary to the intron of an essential viral gene, such as the major immediate early (MIE) gene of human cytomegalovirus (HCMV). Also provided herein are pharmaceutical compositions additionally containing a pharmaceutically acceptable carrier system, wherein the carrier system includes a cationic polymer which releases the scRNA in response to endosomal pH.

Abstract: Disclosed are bruceolides for the treatment of cancer, and oilier diseases, selectively targeting unwanted cells. The disclosed bruceolides may include a site specific cleavable moiety inhibiting the chemotoxic activity until cleaved, i.e., removed, within and/or near a cancer to be treated. As to facilitate selective delivery to cancer tumors, the disclosed bruceolides may be loaded into, attached to or otherwise carried by nanoparticles.

Abstract: The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the ceramide-mediated apoptosis of TNBC cells occurs by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in the subject through the use of an effective amount of salvianolic acid B. In another aspect, salvianolic acid B or its pharmaceutically acceptable salt or solvate is used as a medicament or in the manufacture of a medicament for treating TNBC.

Abstract: Provided is a method for preparing a drug loaded nanoparticle comprising: dissolving a macromonomer, a stabilizer and a crosslinker in a solvent to create a mixture; adding an initiator system to the mixture; dissolving a drug or combination of drugs in an organic phase containing the mixture; and recovering the drug loaded nanoparticle, a composition comprising the drug loaded nanoparticle prepared by the above method, and a method for treating cancer comprising administering the above composition to a subject in need thereof.

Abstract: A method for treating or inhibiting cytomegalovirus infection, including administrating an effective amount of a class of small molecules targeting protein phosphatase 1 (PP1) to a subject in need thereof. A method for inhibiting replication of cytomegalovirus, including contacting cytomegalovirus or cells containing the cytomegalovirus with a class of small molecules targeting protein phosphatase 1 (PP1).

Abstract: Disclosed are bruceolides for the treatment of cancer, and other diseases, selectively targeting unwanted cells. The disclosed bruceolides may include a site specific cleavable moiety inhibiting the chemotoxic activity until cleaved, i.e., removed, within and/or near a cancer to be treated. As to facilitate selective delivery to cancer tumors, the disclosed bruceolides may be loaded into, attached to or otherwise carried by nanoparticles.

Abstract: Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the N2?-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment. Such compounds are less cytotoxic than emetine and are substantially inactive in non-cancerous cells. In one aspect, the compounds described herein can be used for the treatment of metastatic and non-metastatic cancers, including, for example, breast cancer, prostate cancer, lung cancer, and leukemia.

Abstract: A method, computer program, and computer system is provided for fault detection in an electrical network. An inductance between a reference point and a fault is determined at a first time based on measuring a fault current. A resistance between the reference point and the fault may be determined at a second time based on measuring a differential of the fault current as zero. A location of the fault may be identified based on the inductance and the resistance.

Abstract: Covalently linked linear polyethylenimine (PEI) clusters are provided that change conformation depending upon changes in counterion concentrations. The structures may be used for the storage, delivery, and/or transport of substances.

Abstract: The present disclosure provides novel computational methods for identifying potential therapeutic peptides as antivirals, and methods of using viral receptor-derived peptides as antivirals. Further, the present disclosure provides methods of using angiotensin converting enzyme 2 (ACE2)-derived peptides as therapeutic treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused coronavirus disease 2019 (COVID-19).